A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms INEXAS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Sep 2017 Results presented in a Synairgen media release.
    • 06 Sep 2017 According to the Synairgen media release, Company continues to analyse the data from the this trial and expects to make a further announcement regarding the potential of its inhaled interferon-beta drug (SNG0010) shortly.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top